Sbarouni Eftihia, Georgiadou Panagiota, Panagiotakos Demosthenes, Kyrzopoulos Stamatis, Tsiapras Dimitrios, Voudris Vassilis, Kremastinos Dimitrios Th
2nd Department of Cardiology, Onassis Cardiac Surgery Center, Attikon University Hospital, 356 Syngrou Ave., 17674 Athens, Greece.
Clin Chim Acta. 2008 Oct;396(1-2):58-61. doi: 10.1016/j.cca.2008.06.024. Epub 2008 Jun 30.
Ischemia modified albumin (IMA) is considered a biomarker of myocardial ischemia. We sought to investigate whether IMA plasma levels change during pharmacological stress test, in patients with stable coronary artery disease.
We studied 37 patients undergoing non-invasive evaluation with a pharmacological stress test, either with radionuclide myocardial perfusion imaging with adenosine or stress echocardiography with dobutamine. Peripheral venous samples were collected before the stress test (baseline), at the end of adenosine infusion or at the peak dose of dobutamine and 60 min after the completion of the stress test for IMA measurement.
IMA plasma levels significantly increased at peak vs. baseline (91.28+/-9.59 U/ml vs. 97.97+/-9.69 U/ml, p<0.0001) and subsequently, decreased significantly at 60 min compared to peak (97.97+/-9.69 U/ml vs. 94+/-15.22 U/ml, p=0.016), returning to values similar to those at baseline (p=0.134). Similarly, in patients with a negative stress test, IMA significantly increased at peak compared to baseline (91.08+/-10.03 U/ml vs. 99.58+/-8.43 U/ml, p=0.006) and returned to baseline at 60 min (99.58+/-8.43 U/ml vs. 91.83+/-7.93 U/ml, p=0.019), the 60 minute levels being similar to baseline values (p=0.212). Conversely, in patients with a positive stress test, IMA significantly increased at peak compared to baseline (91.38+/-10.13 U/ml vs. 97.17+/-10.34 U/ml, p=0.006) and although decreased at 1 h, this did not reach statistical significance compared either to the baseline or to the peak values (95.04+/-17.76 U/ml vs. 91.38+/-10.13 U/ml, p=0.315 and 95.04+/-17.76 U/ml vs. 97.17+/-10.34 U/ml, p=0.235, respectively).
IMA plasma levels change significantly during pharmacologic stress testing, in patients with coronary artery disease, but with no difference between the positive and the negative tests.
缺血修饰白蛋白（IMA）被认为是心肌缺血的生物标志物。我们旨在研究在稳定型冠状动脉疾病患者进行药物负荷试验期间，IMA血浆水平是否会发生变化。
我们研究了37例接受药物负荷试验进行无创评估的患者，试验采用腺苷放射性核素心肌灌注显像或多巴酚丁胺负荷超声心动图。在负荷试验前（基线）、腺苷输注结束时或多巴酚丁胺峰值剂量时以及负荷试验完成后60分钟采集外周静脉血样以测量IMA。
与基线相比，IMA血浆水平在峰值时显著升高（91.28±9.59 U/ml对97.97±9.69 U/ml，p<0.0001），随后，与峰值相比在60分钟时显著下降（97.97±9.69 U/ml对94±15.22 U/ml，p=0.016），恢复到与基线相似的值（p=0.134）。同样，在负荷试验阴性的患者中，与基线相比，IMA在峰值时显著升高（91.08±10.03 U/ml对99.58±8.43 U/ml，p=0.006），并在60分钟时恢复到基线（99.58±8.43 U/ml对91.83±7.93 U/ml，p=0.019），60分钟时的水平与基线值相似（p=0.212）。相反，在负荷试验阳性的患者中，与基线相比，IMA在峰值时显著升高（91.38±10.13 U/ml对97.17±10.34 U/ml，p=0.006），尽管在1小时时有所下降，但与基线或峰值相比均未达到统计学意义（95.04±17.76 U/ml对91.38±10.13 U/ml，p=0.315以及95.04±17.76 U/ml对97.17±10.34 U/ml，p=0.235）。
在冠状动脉疾病患者进行药物负荷试验期间，IMA血浆水平有显著变化，但阳性和阴性试验之间无差异。
